Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
67.97%
Operating Margin
14.49%
Net Margin
5.87%
Efficiency Metrics
Revenue per Expense Ratio
1.18
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
57.40%
Income Tax Rate
30,100,000.0%
EPS
0.2000000000
Balance Sheet Analysis
Current Ratio
0.87
Cash Ratio
0.08
Working Capital
$-44.63M
Debt to Equity
1.23
Debt to Assets
46.80%
Equity Ratio
38.15%
Cash Flow Analysis
Operating Cash Flow Ratio
47.08%
Free Cash Flow Ratio
23.89%
CapEx to Revenue
23.19%
Dividends Paid
$68.57M
Stock Buybacks
No buybacks
Total Shareholder Returns
$68.57M
Cash Position Change
-21.50%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 5.38%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
3.80%
Net Income
130.46%
EPS
128.99%
Operating Income
76.43%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-5.89%
Operating Cash Flow
16.93%
Free Cash Flow
110.01%
Balance Sheet Health
Assets
-0.27%
Debt
5.80%
Book Value per Share
-5.83%
Inventory
100.00%
Shareholder Returns
Dividends per Share
5.38%
Shares Outstanding
0.75%
Long Term Trends
3Y Revenue/Share
20.27%
5Y Revenue/Share
11.27%
3Y Dividend/Share
23.96%
5Y Dividend/Share
-33.55%